Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

Cancer cachexia is a devastating wasting syndrome that significantly restricts therapeutic options for cancer patients. The development of treatments has been limited by a lack of in-depth ...

An Israeli-American study has uncovered a key mechanism behind cachexia, offering hope to the estimated nine million people suffering from the deadly syndrome that causes severe weight and muscle loss ...

Reimagining Cancer Care for Patients Experiencing Homelessness by Expanding the Traditional Oncology Team Cachexia is a systemic wasting syndrome prevalent in patients with cancer that significantly ...

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...